What is Corcept Therapeutics Incorporated's stock symbol?
Corcept Therapeutics Incorporated trades on the NASDAQ under the ticker symbol "CORT."
Where is Corcept Therapeutics Incorporated's stock going? Where will Corcept Therapeutics Incorporated's stock price be in 2017?
4 brokerages have issued 12-month price targets for Corcept Therapeutics Incorporated's stock. Their forecasts range from $7.00 to $14.00. On average, they expect Corcept Therapeutics Incorporated's stock price to reach $11.25 in the next twelve months.
When will Corcept Therapeutics Incorporated announce their earnings?
Corcept Therapeutics Incorporated is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Corcept Therapeutics Incorporated stock?
Here are some recent quotes from research analysts about Corcept Therapeutics Incorporated stock:
According to Zacks Investment Research, "Corcept announced preliminary results for the fourth quarter 2016 and the full year 2016. The fourth quarter results were almost in line with the Zacks Consensus Estimates while the full year results were short of the Zacks Consensus Estimates. Corcept’s share price movement shows that the stock has underperformed the Zacks classified Medical-Drugs industry in the last 3 months. Corcept is solely dependent on Korlym for growth. A decline in Korlym sales will largely hinder the company’s growth prospects. Although Corcept is working on developing additional candidates, these compounds are still years away from commercialization. Corcept is evaluating its most advanced candidate CORT125134 in a phase I/II study to treat patients with solid-tumor cancers. However, Corcept’s efforts to expand Korlym’s label are encouraging. Label expansion should boost the drug’s commercial potential significantly." (2/2/2017)
FBR & Co analysts commented, "We recently had an opportunity to host investor meetings with Corcept’s CEO, Joseph Belanoff, MD. During the meetings, investors were focused on the Korlym business, which has continued to achieve strong sales growth year over year, and Corcept’s additional pipeline candidates. As a reminder, Korlym (mifepristone) is a glucocorticoid receptor (GR) antagonist approved for the treatment of Cushing’s syndrome. We took a look at the road ahead for Corcept in 2016 and provide four key takeaways: (1) we believe the Korlym business has significant untapped growth remaining; (2) second generation GR antagonist CORT125134 remains underappreciated by the Street in our opinion; (3) mTNBC continues to be a major potential catalyst for the stock; and (4) we expect to see exciting additional programs emerge from the pipeline, given Corcept’s approximately 30 ongoing investigator- sponsored trials (ISTs). Overall, we left the meetings more confident in Corcept’s efforts across the Korlym business and development pipeline and look forward to incremental mTNBC data expected at the American Society of Clinical Oncology (ASCO) meeting in June." (4/27/2016)
Who owns Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Federated Investors Inc. PA (12.50%), Renaissance Technologies LLC (1.36%), State Street Corp (1.13%), Two Sigma Investments LP (0.55%), Menta Capital LLC (0.41%) and GSA Capital Partners LLP (0.34%). Company insiders that own Corcept Therapeutics Incorporated stock include Daniel Bradbury, David L Mahoney, G Leonard Baker Jr, James N Wilson, Joseph C Cook Jr, Joseph K Belanoff, Patrick G Enright and Steven Lo.
Who sold Corcept Therapeutics Incorporated stock? Who is selling Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., GABELLI & Co INVESTMENT ADVISERS INC., Cadence Capital Management LLC, Allianz Asset Management AG, Metropolitan Life Insurance Co. NY, GSA Capital Partners LLP, Federated Investors Inc. PA and Guggenheim Capital LLC. Company insiders that have sold Corcept Therapeutics Incorporated stock in the last year include James N Wilson, Joseph K Belanoff and Patrick G Enright.
Who bought Corcept Therapeutics Incorporated stock? Who is buying Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Investments LP, Bogle Investment Management L P DE, Russell Investments Group Ltd., Intellectus Partners LLC, Oxford Asset Management, Dimensional Fund Advisors LP and Credit Agricole S A.
How do I buy Corcept Therapeutics Incorporated stock?
Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Corcept Therapeutics Incorporated stock cost?
One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $8.30.